In this article, we identify the top 10 most impactful articles for pediatric hospital medicine in 2025, as presented at the ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Don’t let winter ailments slow you down. Discover how understanding your symptoms can lead to powerful relief while embracing ...

Research shows RSV leads to high hospitalization rates in adults, emphasizing the importance of enhanced surveillance and ...

New data hint at a role for the AS01 adjuvant in vaccines for herpes zoster and respiratory syncytial virus in protecting ...

While respiratory syncytial virus (RSV) typically causes mild symptoms in adults, the virus can be life-threatening for infants. The seasonal virus is the most common cause of lower respiratory tract ...